These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32361251)

  • 1. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
    Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
    EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
    Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
    Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
    Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
    Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
    Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
    Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
    Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.
    Murakawa M; Yamamoto N; Kamioka Y; Kamiya M; Kobayashi S; Ueno M; Morimoto M; Atsumi Y; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Morinaga S
    In Vivo; 2020; 34(1):347-353. PubMed ID: 31882498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma.
    Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Updates Surg; 2021 Feb; 73(1):251-259. PubMed ID: 32410163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.